FDA Approval of Orphan Drug Indications for Pediatric Patients, 2011-2023

被引：0
|
作者：
Kakkilaya, Apoorva [1 ]
Shahzad, Mahnum [2 ]
Bourgeois, Florence T. [3 ,4 ,5 ]
机构：
[1] Univ Texas Med Branch, John Sealy Sch Med, Galveston, TX USA
[2] Harvard Med Sch, Dept Populat Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA
[3] Harvard Med Sch, Harvard MIT Ctr Regulatory Sci, Boston, MA USA
[4] Harvard Med Sch, Dept Pediat, Boston, MA USA
[5] Boston Childrens Hosp, Computat Hlth Informat Program, Pediat Therapeut & Regulatory Sci Initiat, Boston, MA USA
来源：
JAMA PEDIATRICS | 2025年 / 179卷 / 02期
关键词：
D O I：
10.1001/jamapediatrics.2024.5280
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：203 / 205
页数：3
相关论文
共 46 条
  • [31] Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs
    Molto Valiente, C.
    Tibau, A.
    Ocana Fernandez, A.
    Templeton, A.
    del Carpio Huerta, L.
    Del Paggio, J.
    Barnadas, A.
    Booth, C.
    Amir, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Investigating disparities in enrollment of patients in lung cancer clinical trials that led to FDA approval for immunotherapies between 2015 and 2023: A comparison with the US population
    Le, Nhu Tuyet
    Nguyen, Ryan Huu-Tuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients.
    Burckart, G.
    Cavaille-Coll, M.
    Duong, A.
    Hothem, L.
    Albrecht, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 714 - 714
  • [34] US Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia
    Ehrlich, Lori A.
    Kwitkowski, Virginia E.
    Reaman, Gregory
    Ko, Chia-Wen
    Nie, Lei
    Pazdur, Richard
    Farrell, Ann T.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (12)
  • [35] Charting Unexplored Territories: ERCP Indications and Complications in Pediatric Patients; A Cross-Sectional Study from 2022 to 2023
    Shahramian, Iraj
    Pandi, Masoume
    Dehghani, Seyed Mohsen
    Haghighat, Mahmood
    Ataollahi, Maryam
    Honar, Naser
    Imanieh, Mohammad Hadi
    Sivandzadeh, Gholam Reza
    Tahani, Masoud
    Taghavi, Ali Reza
    Sharafi, Fateme
    Eslamzadeh, Saghi
    Gohariyan, Halime
    IRANIAN JOURNAL OF PEDIATRICS, 2024, 34 (04)
  • [36] Pediatric Extrapolation Approach for US Food and Drug Administration Approval of Brexpiprazole in Patients Aged 13 to 17 Years with Schizophrenia
    Zhang, Huixia
    Liu, Jie
    Sharma, Vishnu
    Zhuang, Luning
    Horn, Pamela
    Uppoor, Ramana
    Mehta, Mehul
    Zhu, Hao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (07): : 771 - 778
  • [37] Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
    Miller, Kathleen L.
    Fermaglich, Lewis J.
    Maynard, Janet
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [38] Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
    Kathleen L. Miller
    Lewis J. Fermaglich
    Janet Maynard
    Orphanet Journal of Rare Diseases, 16
  • [39] FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy
    Przepiorka, Donna
    Le, Robert Q.
    Ionan, Alexei
    Li, Ruo-Jing
    Wang, Ying-Hong
    Gudi, Ramadevi
    Mitra, Soumya
    Vallejo, Jonathon
    Okusanya, Olanrewaju O.
    Ma, Lian
    Yang, Yuching
    Patel, Paresma
    Mezaache, Djelila
    Shah, Rakhi
    Banerjee, Anamitro
    McLamore, Sherita
    Maung, Adam N.
    Goldberg, Kirsten B.
    Pazdur, Richard
    Theoret, Marc R.
    De Claro, R. Angelo
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2488 - 2492
  • [40] Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients
    Dawn M. Maxey
    D. Dunbar Ivy
    Michelle T. Ogawa
    Jeffrey A. Feinstein
    Pediatric Cardiology, 2013, 34 : 1628 - 1636
12345